Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
146-9251 cream in Ichthyosis Vulgaris
NCT03173547Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Countries
- 1
- Sponsor
- Revance Therapeutics
- Drugs
- tazarotene
- Conditions
- ichthyosis vulgaris (IV)
01
Overview
Phase 2, randomised, double-blind trial in ichthyosis vulgaris (IV) comparing 146-9251 cream with Vehicle cream (2 arms). Primary endpoint: Treatment Success at Day 43. Started Apr 2017; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
146-9251 cream
146-9251 cream applied twice daily.
Vehicle cream
Vehicle cream applied twice daily.
03
Who it enrols
Patients aged 12 and older with moderate to severe ichthyosis vulgaris involving at least 5% BSA, excluding those with other dermatologic disorders or recent use of topical/systemic therapies.
04
Endpoints
Primary
Treatment Success
Beyond the preview
Go deeper on NCT03173547.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173547.